These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
212 related items for PubMed ID: 27144293
41. The crystal structure of transthyretin in complex with diethylstilbestrol: a promising template for the design of amyloid inhibitors. Morais-de-Sá E, Pereira PJ, Saraiva MJ, Damas AM. J Biol Chem; 2004 Dec 17; 279(51):53483-90. PubMed ID: 15469931 [Abstract] [Full Text] [Related]
43. Crystal structures of human transthyretin complexed with glabridin. Yokoyama T, Kosaka Y, Mizuguchi M. J Med Chem; 2014 Feb 13; 57(3):1090-6. PubMed ID: 24422526 [Abstract] [Full Text] [Related]
44. Plasminogen activation triggers transthyretin amyloidogenesis in vitro. Mangione PP, Verona G, Corazza A, Marcoux J, Canetti D, Giorgetti S, Raimondi S, Stoppini M, Esposito M, Relini A, Canale C, Valli M, Marchese L, Faravelli G, Obici L, Hawkins PN, Taylor GW, Gillmore JD, Pepys MB, Bellotti V. J Biol Chem; 2018 Sep 14; 293(37):14192-14199. PubMed ID: 30018138 [Abstract] [Full Text] [Related]
45. Review on the Structures and Activities of Transthyretin Amyloidogenesis Inhibitors. Guo X, Liu Z, Zheng Y, Li Y, Li L, Liu H, Chen Z, Wu L. Drug Des Devel Ther; 2020 Sep 14; 14():1057-1081. PubMed ID: 32210536 [Abstract] [Full Text] [Related]
46. Retinoic acid inhibition of thyroxine binding to human transthyretin. Smith TJ, Davis FB, Deziel MR, Davis PJ, Ramsden DB, Schoenl M. Biochim Biophys Acta; 1994 Jan 05; 1199(1):76-80. PubMed ID: 8280758 [Abstract] [Full Text] [Related]
47. Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses. Johnson SM, Wiseman RL, Sekijima Y, Green NS, Adamski-Werner SL, Kelly JW. Acc Chem Res; 2005 Dec 05; 38(12):911-21. PubMed ID: 16359163 [Abstract] [Full Text] [Related]
49. Systemic optimization and structural evaluation of quinoline derivatives as transthyretin amyloidogenesis inhibitors. Kim B, Park H, Lee SK, Park SJ, Koo TS, Kang NS, Hong KB, Choi S. Eur J Med Chem; 2016 Nov 10; 123():777-787. PubMed ID: 27541261 [Abstract] [Full Text] [Related]
53. The preaggregated state of an amyloidogenic protein: hydrostatic pressure converts native transthyretin into the amyloidogenic state. Ferrão-Gonzales AD, Souto SO, Silva JL, Foguel D. Proc Natl Acad Sci U S A; 2000 Jun 06; 97(12):6445-50. PubMed ID: 10841549 [Abstract] [Full Text] [Related]
57. Cyclodextrin, a novel therapeutic tool for suppressing amyloidogenic transthyretin misfolding in transthyretin-related amyloidosis. Jono H, Anno T, Motoyama K, Misumi Y, Tasaki M, Oshima T, Mori Y, Mizuguchi M, Ueda M, Shono M, Obayashi K, Arima H, Ando Y. Biochem J; 2011 Jul 01; 437(1):35-42. PubMed ID: 21668413 [Abstract] [Full Text] [Related]
58. Transthyretin forms amyloid fibrils at physiological pH with ultrasonication. Misumi Y, Ueda M, Fujimori H, Shinriki S, Meng W, Kim J, Saito S, Obayashi K, Uchino M, Ando Y. Amyloid; 2008 Dec 01; 15(4):234-9. PubMed ID: 19065294 [Abstract] [Full Text] [Related]